Skin Cells Reprogrammed Into Bone-Forming Spheroids Heal Defects in Elderly Patients

Bone diseases disproportionately affect older adults, whose stem cells and native osteoblasts decline in both number and function with age. Current cell-based bone repair strategies rely on mesenchymal stem cells or skeletal stem cells that are increasingly dysfunctional in elderly donors, limiting therapeutic options precisely when they are most needed. This study presents a systematic framework for converting abundant, easily harvested skin fibroblasts into functional osteoblasts using only small molecules — no viral vectors, no genetic modification — and then assembling those cells into transplantable, scaffold-free tissue spheroids.

The reprogramming strategy centered on the WNT/β-catenin signaling pathway, which is essential for osteoblast lineage commitment. Eight small molecules were identified and organized into three sequential treatment modules: CFRVT (CHIR99021, Forskolin, RepSox, Valproic acid, Trichostatin A) for days 1–5, CFRVGSE (adding Go6983, SP600125, EPZ004777) for days 6–12, and CFRV for days 13–18. Each module was selected based on its ability to upregulate specific stage-appropriate transcription factors — c-MYC and RUNX2 in stage one, RUNX2 and DLX5 in stage two, and SP7 in stage three — mimicking the natural developmental timeline of osteoblastogenesis.

Reprogramming efficiency was remarkably high. Nuclear RUNX2 translocation was observed in 96.7% ± 1.9% of treated cells, compared to just 6.0% ± 1.8% in untreated fibroblasts. SP7-positive cells reached 93.7% ± 2.9% in iOBs versus 4.4% ± 1.1% in controls. RNA-seq hierarchical clustering and principal component analysis confirmed that iOBs clustered with bone marrow MSC-derived osteoblasts and were transcriptionally distinct from their fibroblast origin. KEGG pathway enrichment identified upregulation of PTH signaling, MAPK, WNT, and TGF-β pathways — consistent with the small molecules used. Critically, blocking WNT signaling with ICG-001 or XAV939 during reprogramming significantly reduced expression of CTNNB1, WNT5A, RUNX2, DLX5, MYC, and SP7, and sharply diminished osteogenic differentiation capacity, confirming WNT as the essential driver.

The iOBs were then formed into three-dimensional spheroids (iOB-Sps) without any synthetic scaffold material. In vivo experiments in bone defect models demonstrated that iOB-Sps showed improved cell survival post-transplantation compared to dissociated cell suspensions, produced measurable new bone matrix, reduced reactive oxygen species (ROS) levels in the defect microenvironment, and accelerated both endogenous osteogenesis and local angiogenesis. The spheroids functioned as self-scaffolding building blocks, with their size and number customizable to match defect dimensions. Importantly, the protocol worked equivalently across fibroblasts from donors of all ages, including elderly individuals — a critical advantage over stem cell approaches.

The clinical implications are significant. This platform offers a potential autologous therapy: a patient's own skin cells could be harvested, reprogrammed, formed into spheroids, and reimplanted — avoiding immune rejection, donor site morbidity from bone grafts, and the limitations of aging stem cell pools. The scaffold-free format eliminates biomaterial-related complications. Caveats include the study's preclinical nature, the need for larger animal models and eventual human trials, and questions about long-term safety and tumorigenicity of chemically reprogrammed cells that will require rigorous follow-up.